{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:20:03Z","timestamp":1781871603560,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018YFC2000503"],"award-info":[{"award-number":["2018YFC2000503"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81861168038"],"award-info":[{"award-number":["81861168038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81420108005"],"award-info":[{"award-number":["81420108005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2018M641919"],"award-info":[{"award-number":["2018M641919"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Key Clinical Specialty","award":["3030247011"],"award-info":[{"award-number":["3030247011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr Metab (Lond)"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>As a lipid metabolic disorder, non-alcoholic fatty liver disease (NAFLD) is an important cause of cirrhosis and hepatocellular carcinoma, with no effective drug up to date. Previous studies have demonstrated increased methylation levels of key genes in NAFLD, suggesting that hydroxymethylation, a key step in demethylation, may be a possible strategy to reverse NAFLD. TET1 is well known as a key hydroxymethylase, however, its role and mechanism in NAFLD remains unclear.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this study, we utilized TET1 knockout mice, fed with high-fat diet. Furthermore, by ChIP and hMeDIP. TET1 knockdown L02 and HepG2 cell lines.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Their degree of liver steatosis was more severe than that of wild-type mice, suggesting that TET1 had a significant protective effect against NAFLD. We further found that PPAR\u03b1, a key regulator of fatty acid oxidation, and its downstream key enzymes ACOX1 and CPT1A, as well as the fatty acid oxidation product \u03b2-HB were significantly decreased in TET1 knockout mice. While the key genes for fatty acid synthesis and uptake were not significantly changed, suggesting that TET1 inhibits NAFLD by promoting fatty acid oxidation via PPAR\u03b1 pathway. TET1 was confirmed to directly bind to the promoter of PPAR\u03b1 and elevate its hydroxymethylation level.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study is the first to show that TET1 can activate PPAR\u03b1, promote fatty acid oxidation and inhibit NAFLD progression by hydroxymethylation of PPAR\u03b1 promoter, which may be a new strategy to reverse NAFLD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12986-020-00466-8","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T11:03:52Z","timestamp":1592564632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["TET1 promotes fatty acid oxidation and inhibits NAFLD progression by hydroxymethylation of PPAR\u03b1 promoter"],"prefix":"10.1186","volume":"17","author":[{"given":"Jingjie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujen","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiucun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"key":"466_CR1","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.2174\/1381612811319290006","volume":"19","author":"S De Minicis","year":"2013","unstructured":"De Minicis S, Day C, Svegliati-Baroni G. From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights. Curr Pharm Des. 2013;19:5239\u201349. 23394093.","journal-title":"Curr Pharm Des"},{"key":"466_CR2","doi-asserted-by":"publisher","unstructured":"Estes C, Razavi H. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-33. 28802062. https:\/\/doi.org\/10.1002\/hep.29466.","DOI":"10.1002\/hep.29466"},{"key":"466_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/liv.13031","volume":"36","author":"C Margini","year":"2016","unstructured":"Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 2016;36:317\u201324. 26601627. https:\/\/doi.org\/10.1111\/liv.13031.","journal-title":"Liver Int"},{"key":"466_CR4","doi-asserted-by":"publisher","unstructured":"Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients. 2014;6(8):3303-25. https:\/\/doi.org\/10.3390\/nu6083303.","DOI":"10.3390\/nu6083303"},{"key":"466_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2017.10.015","volume":"68","author":"MA Konerman","year":"2018","unstructured":"Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepatol. 2018;68:362\u201375. 29122694. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.015.","journal-title":"J Hepatol"},{"key":"466_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature12750","volume":"502","author":"RM Kohli","year":"2013","unstructured":"Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502:472\u20139. 24153300. https:\/\/doi.org\/10.1038\/nature12750.","journal-title":"Nature"},{"key":"466_CR7","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1242\/dev.070771","volume":"139","author":"L Tan","year":"2012","unstructured":"Tan L, Shi YG. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development. 2012;139:1895\u2013902. 22569552. https:\/\/doi.org\/10.1242\/dev.070771.","journal-title":"Development"},{"key":"466_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2013.12.019","volume":"156","author":"H Wu","year":"2014","unstructured":"Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell. 2014;156:45\u201368. 24439369. https:\/\/doi.org\/10.1016\/j.cell.2013.12.019.","journal-title":"Cell"},{"key":"466_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mam.2016.11.008","volume":"54","author":"J Lee","year":"2017","unstructured":"Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Asp Med. 2017;54:78\u201388. 27889327. https:\/\/doi.org\/10.1016\/j.mam.2016.11.008.","journal-title":"Mol Asp Med"},{"key":"466_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/gutjnl-2016-311526","volume":"66","author":"T Hardy","year":"2017","unstructured":"Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut. 2017;66:1321\u20138. 27002005. https:\/\/doi.org\/10.1136\/gutjnl-2016-311526.","journal-title":"Gut"},{"key":"466_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2337\/db15-1716","volume":"66","author":"C Baumeier","year":"2017","unstructured":"Baumeier C, Saussenthaler S, Kammel A, Jahnert M, Schluter L, Hesse D, et al. Hepatic DPP4 DNA methylation associates with fatty liver. Diabetes. 2017;66:25\u201335. 27999105. https:\/\/doi.org\/10.2337\/db15-1716.","journal-title":"Diabetes"},{"key":"466_CR12","doi-asserted-by":"publisher","first-page":"e1480","DOI":"10.1097\/md.0000000000001480","volume":"94","author":"CJ Pirola","year":"2015","unstructured":"Pirola CJ, Scian R, Gianotti TF, Dopazo H, Rohr C, Martino JS, et al. Epigenetic modifications in the biology of nonalcoholic fatty liver disease: the role of DNA Hydroxymethylation and TET proteins. Medicine (Baltimore). 2015;94:e1480. 26356709. https:\/\/doi.org\/10.1097\/md.0000000000001480.","journal-title":"Medicine (Baltimore)"},{"key":"466_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720\u201333. 25450203. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.039.","journal-title":"J Hepatol"},{"key":"466_CR14","doi-asserted-by":"publisher","unstructured":"Del Campo JA, Gallego-Duran R, Gallego P, Grande L. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J Mol Sci. 2018;19. 29562725. https:\/\/doi.org\/10.3390\/ijms19030911.","DOI":"10.3390\/ijms19030911"},{"key":"466_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","volume":"64","author":"CJ Pirola","year":"2015","unstructured":"Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800\u201312. 24973316. https:\/\/doi.org\/10.1136\/gutjnl-2014-306996.","journal-title":"Gut"},{"key":"466_CR16","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2012-302962","volume":"62","author":"CJ Pirola","year":"2013","unstructured":"Pirola CJ, Gianotti TF, Burgueno AL, Rey-Funes M, Loidl CF, Mallardi P, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. 2013;62:1356\u201363. 22879518. https:\/\/doi.org\/10.1136\/gutjnl-2012-302962.","journal-title":"Gut"},{"key":"466_CR17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1126\/science.356.6343.1135-d","volume":"356","author":"BA Purnell","year":"2017","unstructured":"Purnell BA. TET function in development. Science. 2017;356:1135\u20136. 28619933. https:\/\/doi.org\/10.1126\/science.356.6343.1135-d.","journal-title":"Science"},{"key":"466_CR18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/nar\/gkx1197","volume":"46","author":"S Burr","year":"2018","unstructured":"Burr S, Caldwell A, Chong M, Beretta M, Metcalf S, Hancock M, et al. Oxygen gradients can determine epigenetic asymmetry and cellular differentiation via differential regulation of Tet activity in embryonic stem cells. Nucleic Acids Res. 2018;46:1210\u201326. 29186571. https:\/\/doi.org\/10.1093\/nar\/gkx1197.","journal-title":"Nucleic Acids Res"},{"key":"466_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature19081","volume":"537","author":"B Thienpont","year":"2016","unstructured":"Thienpont B, Steinbacher J, Zhao H, D'Anna F, Kuchnio A, Ploumakis A, et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature. 2016;537:63\u20138. 27533040. https:\/\/doi.org\/10.1038\/nature19081.","journal-title":"Nature"},{"key":"466_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/ni.3148","volume":"16","author":"L Cimmino","year":"2015","unstructured":"Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol. 2015;16:653\u201362. 25867473. https:\/\/doi.org\/10.1038\/ni.3148.","journal-title":"Nat Immunol"},{"key":"466_CR21","doi-asserted-by":"publisher","unstructured":"Prasad P, Mittal SA. Hypoxia-Mediated Epigenetic Regulation of Stemness in Brain Tumor Cells. Stem Cells. 2017;35:1468\u201378. 28376560. https:\/\/doi.org\/10.1002\/stem.2621.","DOI":"10.1002\/stem.2621"},{"key":"466_CR22","doi-asserted-by":"publisher","unstructured":"Khan R, Bril F, Cusi K, Newsome PN. Modulation of Insulin Resistance in NAFLD. Hepatology. 2018. 30556145. https:\/\/doi.org\/10.1002\/hep.30429.","DOI":"10.1002\/hep.30429"},{"key":"466_CR23","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088\u201393. 9808609.","journal-title":"Circulation"},{"key":"466_CR24","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/eurheartj\/ehv291","volume":"36","author":"AV Khera","year":"2015","unstructured":"Khera AV, Millar JS, Ruotolo G, Wang MD, Rader DJ. Potent peroxisome proliferator-activated receptor-alpha agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015;36:3020\u20132. 26112886. https:\/\/doi.org\/10.1093\/eurheartj\/ehv291.","journal-title":"Eur Heart J"},{"key":"466_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","volume":"40","author":"C Fernandez-Miranda","year":"2008","unstructured":"Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40:200\u20135. 18261709. https:\/\/doi.org\/10.1016\/j.dld.2007.10.002.","journal-title":"Dig Liver Dis"},{"key":"466_CR26","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/hep.26461","volume":"58","author":"B Staels","year":"2013","unstructured":"Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941\u201352. 23703580. https:\/\/doi.org\/10.1002\/hep.26461.","journal-title":"Hepatology"},{"key":"466_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","volume":"66","author":"Y Rotman","year":"2017","unstructured":"Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180\u201390. 27646933. https:\/\/doi.org\/10.1136\/gutjnl-2016-312431.","journal-title":"Gut"},{"key":"466_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1289\/ehp.1307047","volume":"122","author":"ZJ Ge","year":"2014","unstructured":"Ge ZJ, Luo SM, Lin F, Liang QX, Huang L, Wei YC, et al. DNA methylation in oocytes and liver of female mice and their offspring: effects of high-fat-diet-induced obesity. Environ Health Perspect. 2014;122:159\u201364. 24316659. https:\/\/doi.org\/10.1289\/ehp.1307047.","journal-title":"Environ Health Perspect"},{"key":"466_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbrc.2015.10.134","volume":"468","author":"K Ohashi","year":"2015","unstructured":"Ohashi K, Munetsuna E, Yamada H, Ando Y, Yamazaki M, Taromaru N, et al. High fructose consumption induces DNA methylation at PPARalpha and CPT1A promoter regions in the rat liver. Biochem Biophys Res Commun. 2015;468:185\u20139. 26519879. https:\/\/doi.org\/10.1016\/j.bbrc.2015.10.134.","journal-title":"Biochem Biophys Res Commun"},{"key":"466_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150:1147\u201359.e1145. PMID:26874076. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.038.","journal-title":"Gastroenterology"},{"key":"466_CR31","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1093\/nar\/gks155","volume":"40","author":"H Hashimoto","year":"2012","unstructured":"Hashimoto H, Liu Y, Upadhyay AK, Chang Y, Howerton SB, Vertino PM, et al. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 2012;40:4841\u20139. 22362737. https:\/\/doi.org\/10.1093\/nar\/gks155.","journal-title":"Nucleic Acids Res"},{"key":"466_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/0008-5472.can-06-3123","volume":"67","author":"V Valinluck","year":"2007","unstructured":"Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007;67:946\u201350. 17283125. https:\/\/doi.org\/10.1158\/0008-5472.can-06-3123.","journal-title":"Cancer Res"}],"container-title":["Nutrition &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-020-00466-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12986-020-00466-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-020-00466-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:24:48Z","timestamp":1626222288000},"score":1,"resource":{"primary":{"URL":"https:\/\/nutritionandmetabolism.biomedcentral.com\/articles\/10.1186\/s12986-020-00466-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1186\/s12986-020-00466-8","relation":{},"ISSN":["1743-7075"],"issn-type":[{"value":"1743-7075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal protocol was approved by the institutional Animal Care and Use Committee at the Fudan University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}